NCT02607670Unknown2 期
A Phase 2, Randomized, Double-blind, Placebo-controlled Study of TAT4 Gel for the Reduction of Nasolabial Folds
适应症
干预措施
试验速览
- 阶段
- 2 期
- 入组人数
- 111
- 试验地点
- 1
- 主要终点
- Nasolabial Fold Severity Scale (Clinician-Reported)
研究概览
简要总结
This is a Phase 2, randomized, double-blind, placebo-controlled study of TAT4 Gel for the reduction of moderate to severe nasolabial folds.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 35 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Moderate to severe, bilateral nasolabial folds
- •Must understand and provide informed consent
排除标准
- •Pregnant or lactating women
- •History of skin hypersensitivity of atopic dermatitis
- •Any illness of disease that, in the investigator's opinion, would make trial participation inadvisable
研究组 & 干预措施
TAT4 Gel
Experimental
The participant will apply TAT4 Gel to the nasolabial fold area once daily.
干预措施: TAT4 Gel (Drug)
Placebo
Placebo Comparator
The participant will apply Placebo Gel to the nasolabial fold area once daily.
干预措施: Matching placebo (Drug)
结局指标
主要结局
Nasolabial Fold Severity Scale (Clinician-Reported)
时间窗: Day 91
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
A Clinical Trial of PRAX-114 in Participants With Post-Traumatic Stress DisorderPost Traumatic Stress DisorderStress DisorderStress Disorders, Post-TraumaticTrauma and Stressor Related DisordersPost-traumatic Stress DisorderMental DisorderNCT05260541Praxis Precision Medicines11
已完成
2 期
Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled AsthmaAsthmaNCT05251259AstraZeneca670
已完成
2 期
A Study of Oxidative Pathways in MS FatigueFatigueProgressive Multiple SclerosisNCT02804594University of California, San Francisco15
已完成
2 期
Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer PatientsLocally Recurrent and Metastatic Breast CancerNCT00511459Amgen228
已完成
2 期
A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous FatSubcutaneous FatNCT05736107Caliway Biopharmaceuticals Co., Ltd.107